Analyst Martin Comtesse from Jefferies maintained a Buy rating on Redcare Pharmacy and keeping the price target at €170.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Martin Comtesse has given his Buy rating due to a combination of factors that highlight Redcare Pharmacy’s potential for growth. Despite a softer quarter in the German Rx segment, which was influenced by seasonal factors such as bank holidays, the company’s overall sales were in line with expectations. This indicates a stable performance amidst temporary challenges.
Furthermore, the management’s confidence in maintaining the EBITDA margin above 2% and their reaffirmation of the full-year guidance for 2025 suggest a positive outlook. These elements combined provide a strong foundation for the Buy rating, as they reflect the company’s resilience and potential for future growth.
In another report released on June 30, Deutsche Bank also maintained a Buy rating on the stock with a €214.00 price target.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of 0RJT in relation to earlier this year.